

Carlos Cordon-Cardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7592171/publications.pdf>

Version: 2024-02-01

371
papers

63,951
citations

813
118
h-index

851
244
g-index

390
all docs

390
docs citations

390
times ranked

71635
citing authors

#	ARTICLE	IF	CITATIONS
1	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, 2022, 71, 2069-2080.	12.1	24
2	MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. Cancer Letters, 2022, 525, 46-54.	7.2	19
3	Creating surveillance data infrastructure using laboratory analytics: Leveraging vision and epic systems to support COVID-19 pandemic response. Journal of Pathology Informatics, 2022, 13, 100164.	1.7	0
4	Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence. Acta Neuropathologica Communications, 2022, 10, 21.	5.2	8
5	Food for thought: Eating before saliva collection and interference with SARS-CoV-2 detection. Journal of Medical Virology, 2022, 94, 2471-2478.	5.0	6
6	Hotspots for SARS-CoV-2 Omicron variant spread: Lessons from New York City. Journal of Medical Virology, 2022, 94, 2911-2914.	5.0	6
7	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell, 2022, 40, 441-443.	16.8	29
8	Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multitarget approach. Journal of Medical Virology, 2022, 94, 1606-1616.	5.0	9
9	RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Reflects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City. Journal of Molecular Diagnostics, 2022, , .	2.8	3
10	Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. Cancers, 2022, 14, 2734.	3.7	5
11	The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. MSphere, 2022, 7, .	2.9	16
12	Neutralizing Antibody Responses in COVID-19 Convalescent Sera. Journal of Infectious Diseases, 2021, 223, 47-55.	4.0	70
13	AKI in Hospitalized Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2021, 32, 151-160.	6.1	500
14	Association of SARS-CoV-2 viral load at admission with in-hospital acute kidney injury: A retrospective cohort study. PLoS ONE, 2021, 16, e0247366.	2.5	5
15	Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From Fatal Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 223, 1842-1854.	4.0	33
16	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Modern Pathology, 2021, 34, 1456-1467.	5.5	184
17	RT-PCR/MALDI-TOF mass spectrometry-based detection of SARS-CoV-2 in saliva specimens. Journal of Medical Virology, 2021, 93, 5481-5486.	5.0	29
18	The human leukocyte antigen as a candidate tumor suppressor. Cancer Cell, 2021, 39, 586-589.	16.8	7

#	ARTICLE	IF	CITATIONS
19	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 301.e17-301.e28.	1.6	7
20	Analysis of sex-specific risk factors and clinical outcomes in COVID-19. <i>Communications Medicine</i> , 2021, 1, .	4.2	23
21	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021, 160, 2435-2450.e34.	1.3	118
22	Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. <i>Nature Communications</i> , 2021, 12, 3463.	12.8	18
23	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1028-1030.	16.8	176
24	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. <i>Human Pathology</i> , 2021, 114, 110-119.	2.0	32
25	Molecular Profiling of Coronavirus Disease 2019 (COVID-19) Autopsies Uncovers Novel Disease Mechanisms. <i>American Journal of Pathology</i> , 2021, 191, 2064-2071.	3.8	14
26	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 734963.	2.8	4
27	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. <i>Academic Pathology</i> , 2021, 8, 23742895211006818.	1.1	5
28	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1442-1444.	16.8	62
29	Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment. <i>Blood</i> , 2021, 138, 822-822.	1.4	2
30	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. <i>Heliyon</i> , 2021, 7, e08444.	3.2	8
31	COVID-19: Staging of a New Disease. <i>Cancer Cell</i> , 2020, 38, 594-597.	16.8	48
32	Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3594-3596.e3.	3.8	72
33	Molecular tracing of prostate cancer lethality. <i>Oncogene</i> , 2020, 39, 7225-7238.	5.9	10
34	Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. <i>Lancet Microbe</i> , The, 2020, 1, e283-e289.	7.3	133
35	Retrospective cohort study of clinical characteristics of 2199 hospitalised patients with COVID-19 in New York City. <i>BMJ Open</i> , 2020, 10, e040736.	1.9	50
36	SARS-CoV-2 viral load predicts COVID-19 mortality. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, e70.	10.7	432

#	ARTICLE	IF	CITATIONS
37	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. <i>Science</i> , 2020, 370, 1227-1230.	12.6	1,035
38	Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1815-1826.	2.8	383
39	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , 2020, 26, 1636-1643.	30.7	1,860
40	Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. <i>Nature Medicine</i> , 2020, 26, 1708-1713.	30.7	405
41	Screening peripheral biopsies for alpha-synuclein pathology using deep machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, e047358.	0.8	0
42	Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies. <i>International Journal of Infectious Diseases</i> , 2020, 96, 431-439.	3.3	43
43	Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. <i>Journal of Medical Virology</i> , 2020, 92, 5.0 1695-1698.	5.0	97
44	Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation. <i>Journal of Medical Internet Research</i> , 2020, 22, e24018.	4.3	174
45	Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells. <i>Aging</i> , 2020, 12, 17694-17712.	3.1	2
46	Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	1
47	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. <i>Cell Research</i> , 2019, 29, 628-640.	12.0	121
48	exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids. <i>Cell</i> , 2019, 177, 463-477.e15.	28.9	228
49	Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy. <i>Laboratory Investigation</i> , 2019, 99, 1019-1029.	3.7	79
50	Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. <i>Stem Cell Research</i> , 2019, 41, 101637.	0.7	0
51	Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. <i>Journal of Clinical Investigation</i> , 2019, 129, 786-801.	8.2	50
52	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , 2018, 50, 206-218.	21.4	229
53	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. <i>Journal of Cardiac Failure</i> , 2018, 24, 78-86.	1.7	10
54	Integrated nanoscale deterministic lateral displacement arrays for separation of extracellular vesicles from clinically-relevant volumes of biological samples. <i>Lab on A Chip</i> , 2018, 18, 3913-3925.	6.0	129

#	ARTICLE	IF	CITATIONS
55	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018, 9, 3503.	12.8	224
56	Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 48, 233-238.	3.0	13
57	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. <i>Oncogene</i> , 2018, 37, 5858-5872.	5.9	20
58	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 594-603.	3.9	22
59	Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. <i>Journal of Clinical Investigation</i> , 2018, 129, 215-222.	8.2	16
60	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. <i>Journal of Cell Biology</i> , 2017, 216, 641-656.	5.2	35
61	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. <i>Genes and Development</i> , 2017, 31, 553-566.	5.9	87
62	Reappraising hyalinizing clear cell carcinoma: A population-based study with molecular confirmation. <i>Head and Neck</i> , 2017, 39, 503-511.	2.0	29
63	PTEN counteracts FBXL2 to promote IP3R3- and Ca2+-mediated apoptosis limiting tumour growth. <i>Nature</i> , 2017, 546, 554-558.	27.8	182
64	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 115-123.	3.8	8
65	Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	7
66	Targeting sarcoma tumor-initiating cells through differentiation therapy. <i>Stem Cell Research</i> , 2017, 21, 117-123.	0.7	9
67	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	27.8	142
68	The role of GATA2 in lethal prostate cancer aggressiveness. <i>Nature Reviews Urology</i> , 2017, 14, 38-48.	3.8	71
69	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016, 70, 771-775.	1.9	69
70	The metabolic co-regulator PGC1 α suppresses prostate cancer metastasis. <i>Nature Cell Biology</i> , 2016, 18, 645-656.	10.3	176
71	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. <i>American Journal of Pathology</i> , 2016, 186, 3131-3145.	3.8	28
72	H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. <i>Journal of Pediatric Urology</i> , 2016, 12, 91.e1-91.e7.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Immunopathologic Assessment of PTEN Expression. <i>Methods in Molecular Biology</i> , 2016, 1388, 23-37.	0.9	8
74	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4538-4538.	1.6	6
75	Protein Profiling of Bladder Urothelial Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161922.	2.5	9
76	Function of microRNA activity by ActMiR in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4531-4531.	1.6	0
77	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16002-e16002.	1.6	0
78	Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. <i>Journal of Visualized Experiments</i> , 2015,, 53182.	0.3	40
79	MYC Drives <i>Pten/Trp53</i> -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. <i>Cancer Discovery</i> , 2015, 5, 636-651.	9.4	65
80	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. <i>Cancer Discovery</i> , 2015, 5, 550-563.	9.4	24
81	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	16.8	128
82	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	12.8	240
83	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. <i>Methods</i> , 2015, 77-78, 25-30.	3.8	16
84	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. <i>Cancer Discovery</i> , 2015, 5, 396-409.	9.4	22
85	Inhibition of the autocrine IL-6/JAK2-STAT3-calprotectin axis as targeted therapy for HR ⁺ /HER2 ⁺ breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.	5.9	94
86	Limited miR-17-92 overexpression drives hematologic malignancies. <i>Leukemia Research</i> , 2015, 39, 335-341.	0.8	19
87	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2015, 21, 1182-1189.	30.7	180
88	<i>PI3K/AKT</i> pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. <i>Cancer Medicine</i> , 2015, 4, 1258-1271.	2.8	37
89	Loss of Sirt1 Promotes Prostatic Intraepithelial Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria. <i>American Journal of Pathology</i> , 2015, 185, 266-279.	3.8	51
90	¹²⁵ I-Np63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder Cancer. <i>Journal of Urology</i> , 2015, 193, 1144-1150.	0.4	21

#	ARTICLE	IF	CITATIONS
91	Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. <i>Oncoscience</i> , 2015, 2, 607-614.	2.2	38
92	Prostate cancer prognosis via integrative and co-localized glandular morphometry and immunofluorescent protein biomarker expression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 262-262.	1.6	1
93	Characterization of molecular features of pediatric urothelial bladder carcinomas.. <i>Journal of Clinical Oncology</i> , 2015, 33, 345-345.	1.6	0
94	Incorporation of advanced image analysis in novel post-prostatectomy systems pathology models as an approach to replace the clinical Gleason and provide robust risk stratification.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16134-e16134.	1.6	0
95	The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor β^2 in Mammary Epithelial Cells. <i>Molecular and Cellular Biology</i> , 2014, 34, 4216-4231.	2.3	39
96	FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju107.	6.3	87
97	Genomic analysis in active surveillance. <i>Current Opinion in Urology</i> , 2014, 24, 303-310.	1.8	7
98	Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1036-1044.e3.	1.2	15
99	The <i>miR-424(322)/503</i> cluster orchestrates remodeling of the epithelium in the involuting mammary gland. <i>Genes and Development</i> , 2014, 28, 765-782.	5.9	66
100	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 1023-1031.	3.1	2
101	RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of <i>Pten</i> -Mutant Metastasis. <i>Cancer Discovery</i> , 2014, 4, 318-333.	9.4	83
102	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2014, 20, 1130-1137.	30.7	349
103	Bladder cancers arise from distinct urothelial sub-populations. <i>Nature Cell Biology</i> , 2014, 16, 982-991.	10.3	163
104	Isolation of Cancer Stem Cells From Human Prostate Cancer Samples. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	4
105	Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e98786.	2.5	43
106	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. <i>Journal of Clinical Oncology</i> , 2014, 32, 111-111.	1.6	0
107	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16002-e16002.	1.6	0
108	AAAN-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. <i>Blood</i> , 2014, 124, 487-487.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Biomarkers for bladder cancer management: present and future. American Journal of Clinical and Experimental Urology, 2014, 2, 1-14.	0.4	36
110	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	16.8	220
111	A Common MicroRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ with Normal Umbrella Cells. American Journal of Pathology, 2013, 182, 1171-1179.	3.8	26
112	Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling. American Journal of Pathology, 2013, 182, 2015-2027.	3.8	21
113	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics, 2013, 45, 747-755.	21.4	138
114	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nature Genetics, 2013, 45, 739-746.	21.4	134
115	Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. Genes and Cancer, 2012, 3, 599-603.	1.9	4
116	Perioperative Polyphenon E, a Green Tea Extract, Does Not Affect the Wound Complication Rate in Mice After Sham Laparotomy yet Has an Inhibitory Effect on Wound Healing. Surgical Innovation, 2012, 19, 399-406.	0.9	3
117	Preclinical Analysis of the β -Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2012, 11, 1565-1575.	4.1	104
118	Translocation Renal Cell Carcinomas in Adults. American Journal of Surgical Pathology, 2012, 36, 654-662.	3.7	98
119	Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells. Cancer Cell, 2012, 22, 373-388.	16.8	368
120	miR-143, miR-222, and miR-452 Are Useful as Tumor Stratification and Noninvasive Diagnostic Biomarkers for Bladder Cancer. American Journal of Pathology, 2012, 180, 1808-1815.	3.8	142
121	CpG ODN, Toll Like Receptor (TLR)-9 Agonist, Inhibits Metastatic Colon Adenocarcinoma in a Murine Hepatic Tumor Model. Journal of Surgical Research, 2012, 174, 284-290.	1.6	16
122	A BAC-Based Transgenic Mouse Specifically Expresses an Inducible Cre in the Urothelium. PLoS ONE, 2012, 7, e35243.	2.5	12
123	PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clinical and Translational Oncology, 2012, 14, 197-206.	2.4	16
124	A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer. BJU International, 2012, 109, 207-213.	2.5	5
125	Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery. BJU International, 2012, 109, 40-45.	2.5	6
126	Targeting Nonclassical Oncogenes for Therapy in T-ALL. Cancer Cell, 2012, 21, 459-472.	16.8	84

#	ARTICLE	IF	CITATIONS
127	A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2â€“T4aN0â€“N2M0 bladder cancer. <i>Cancer</i> , 2012, 118, 358-364.	4.1	34
128	PPARÎ³ agonists enhance ET-743â€“induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 886-898.	8.2	56
129	Therapeutic Utility of PI3KÎ³ Inhibition in Leukemogenesis and Tumor Cell Survival. <i>Blood</i> , 2012, 120, 1492-1492.	1.4	1
130	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. <i>Blood</i> , 2012, 120, 285-285.	1.4	5
131	Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. <i>American Journal of Pathology</i> , 2011, 178, 1350-1360.	3.8	114
132	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. <i>American Journal of Pathology</i> , 2011, 179, 540-546.	3.8	44
133	Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression. <i>Cancer Cell</i> , 2011, 20, 173-186.	16.8	158
134	Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. <i>Clinical and Translational Oncology</i> , 2011, 13, 194-203.	2.4	15
135	Three-Dimensional Culture of Mouse Renal Carcinoma Cells in Agarose Macrobeads Selects for a Subpopulation of Cells with Cancer Stem Cell or Cancer Progenitor Properties. <i>Cancer Research</i> , 2011, 71, 716-724.	0.9	50
136	Disruption of a <i>Sirt1</i>-Dependent Autophagy Checkpoint in the Prostate Results in Prostatic Intraepithelial Neoplasia Lesion Formation. <i>Cancer Research</i> , 2011, 71, 964-975.	0.9	65
137	A Role for PML in Innate Immunity. <i>Genes and Cancer</i> , 2011, 2, 10-19.	1.9	49
138	Hydrophilic Agarose Macrobead Cultures Select for Outgrowth of Carcinoma Cell Populations That Can Restrict Tumor Growth. <i>Cancer Research</i> , 2011, 71, 725-735.	0.9	17
139	Personalized approach to prostate cancer prognosis. <i>Archivos Espanoles De Urologia</i> , 2011, 64, 783-91.	0.2	1
140	Galectin-3 expression is associated with bladder cancer progression and clinical outcome. <i>Tumor Biology</i> , 2010, 31, 277-285.	1.8	59
141	Single nucleotide polymorphisms of 8 inflammationâ€“related genes and their associations with smokingâ€“related cancers. <i>International Journal of Cancer</i> , 2010, 127, 2169-2182.	5.1	36
142	Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. <i>Nature</i> , 2010, 464, 374-379.	27.8	357
143	PHF6 mutations in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2010, 42, 338-342.	21.4	282
144	The TLX1 oncogene drives aneuploidy in T cell transformation. <i>Nature Medicine</i> , 2010, 16, 1321-1327.	30.7	139

#	ARTICLE	IF	CITATIONS
145	Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. <i>BJU International</i> , 2010, 105, 462-467.	2.5	59
146	Integrative Genome Comparison of Primary and Metastatic Melanomas. <i>PLoS ONE</i> , 2010, 5, e10770.	2.5	166
147	Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. <i>Carcinogenesis</i> , 2010, 31, 1264-1271.	2.8	36
148	Impact of Stromal Sensitivity on Radiation Response of Tumors Implanted in SCID Hosts Revisited. <i>Cancer Research</i> , 2010, 70, 8179-8186.	0.9	57
149	Association of Nuclear Localization of a Long Interspersed Nuclear Element-1 Protein in Breast Tumors with Poor Prognostic Outcomes. <i>Genes and Cancer</i> , 2010, 1, 115-124.	1.9	76
150	Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 240-248.	7.0	141
151	Molecular pathways of urothelial development and bladder tumorigenesis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 401-408.	1.6	228
152	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 471-471.	1.4	0
153	Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles. <i>Clinical Cancer Research</i> , 2009, 15, 3842-3849.	7.0	34
154	Inactivation of <i>p53</i> and <i>Pten</i> promotes invasive bladder cancer. <i>Genes and Development</i> , 2009, 23, 675-680.	5.9	268
155	3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma. <i>Cancer Research</i> , 2009, 69, 6299-6306.	0.9	126
156	Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer. <i>Cancer Prevention Research</i> , 2009, 2, 1008-1014.	1.5	75
157	Comparison of models to predict clinical failure after radical prostatectomy. <i>Cancer</i> , 2009, 115, 303-310.	4.1	17
158	Systems pathology. <i>Cancer</i> , 2009, 115, 3078-3084.	4.1	21
159	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. <i>Nature Genetics</i> , 2009, 41, 619-624.	21.4	595
160	β -secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2009, 15, 50-58.	30.7	417
161	Correlation of MR Imaging and MR Spectroscopic Imaging Findings with Ki-67, Phospho-Akt, and Androgen Receptor Expression in Prostate Cancer. <i>Radiology</i> , 2009, 250, 803-812.	7.3	29
162	Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?. <i>Cancer Letters</i> , 2009, 279, 126-136.	7.2	119

#	ARTICLE	IF	CITATIONS
163	Cyip1 Is a Putative Invasion Suppressor in Epithelial Cancers. <i>Cell</i> , 2009, 137, 1047-1061.	28.9	77
164	MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1135-1144.	2.4	126
165	<i>miR-19</i> is a key oncogenic component of <i>mir-17-92</i> . <i>Genes and Development</i> , 2009, 23, 2839-2849.	5.9	540
166	Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis. <i>Science Signaling</i> , 2009, 2, ra2.	3.6	64
167	Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. <i>Journal of Urology</i> , 2009, 182, 125-132.	0.4	52
168	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL. <i>Blood</i> , 2009, 114, 142-142.	1.4	8
169	Chk2 Suppresses the Oncogenic Potential of DNA Replication-Associated DNA Damage. <i>Molecular Cell</i> , 2008, 31, 21-32.	9.7	58
170	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. <i>American Journal of Pathology</i> , 2008, 172, 1069-1080.	3.8	65
171	Gli Activity Correlates with Tumor Grade in Platelet-Derived Growth Factor-Induced Gliomas. <i>Cancer Research</i> , 2008, 68, 2241-2249.	0.9	160
172	p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. <i>Journal of Cell Science</i> , 2008, 121, 4098-4105.	2.0	29
173	Identification of PMF1 Methylation in Association with Bladder Cancer Progression. <i>Clinical Cancer Research</i> , 2008, 14, 8236-8243.	7.0	37
174	Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2008, 26, 3923-3929.	1.6	85
175	Aberrant <i>Rheb</i> -mediated mTORC1 activation and <i>Pten</i> haploinsufficiency are cooperative oncogenic events. <i>Genes and Development</i> , 2008, 22, 2172-2177.	5.9	109
176	A context dependent role for Wnt signaling in tumorigenesis and stem cells. <i>Cell Cycle</i> , 2008, 7, 720-724.	2.6	21
177	<i>DLC1</i> is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. <i>Genes and Development</i> , 2008, 22, 1439-1444.	5.9	167
178	TREK-1 Is a Novel Molecular Target in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 1197-1203.	0.9	99
179	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. <i>Journal of Clinical Investigation</i> , 2008, 118, 3051-64.	8.2	319
180	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. <i>Blood</i> , 2008, 112, 298-298.	1.4	3

#	ARTICLE	IF	CITATIONS
181	Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16633-16638.	7.1	243
182	Role of the chromobox protein CBX7 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5389-5394.	7.1	150
183	Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase-Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer. Cancer Research, 2007, 67, 7106-7112.	0.9	128
184	Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors. Clinical Cancer Research, 2007, 13, 4511-4518.	7.0	29
185	NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN. Cell, 2007, 128, 129-139.	28.9	630
186	Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression. Cell, 2007, 128, 141-156.	28.9	652
187	Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. American Journal of Pathology, 2007, 171, 1650-1658.	3.8	30
188	Technology Insight: will systems pathology replace the pathologist?. Nature Reviews Urology, 2007, 4, 39-45.	1.4	33
189	A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer. Clinical Cancer Research, 2007, 13, 3215-3220.	7.0	54
190	Tissue-specific and reversible RNA interference in transgenic mice. Nature Genetics, 2007, 39, 914-921.	21.4	170
191	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine, 2007, 13, 748-753.	30.7	275
192	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine, 2007, 13, 1203-1210.	30.7	804
193	Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1. EMBO Journal, 2007, 26, 4683-4693.	7.8	50
194	Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 2007, 445, 656-660.	27.8	2,159
195	Prognostic significance of p27Kip1 expression in bladder cancer. BJU International, 2007, 100, 259-263.	2.5	33
196	Mad2 Overexpression Promotes Aneuploidy and Tumorigenesis in Mice. Cancer Cell, 2007, 11, 9-23.	16.8	556
197	Molecular Alterations Associated With Bladder Cancer Progression. Seminars in Oncology, 2007, 34, 75-84.	2.2	58
198	Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. Journal of Clinical Investigation, 2007, 117, 314-325.	8.2	101

#	ARTICLE	IF	CITATIONS
199	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation, 2007, 117, 3248-3257.	8.2	167
200	Improved prediction of prostate cancer recurrence through systems pathology. Journal of Clinical Investigation, 2007, 117, 1876-1883.	8.2	102
201	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL. Blood, 2007, 110, 151-151.	1.4	4
202	P1-181: Clinical significance of the AKT pathway in small cell lung cancer and other neuroendocrine tumors. Journal of Thoracic Oncology, 2007, 2, S809.	1.1	0
203	Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study. Anticancer Research, 2007, 27, 283-8.	1.1	30
204	Profiling Bladder Cancer Using Targeted Antibody Arrays. American Journal of Pathology, 2006, 168, 93-103.	3.8	162
205	Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. Cell, 2006, 125, 1253-1267.	28.9	989
206	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. Cell, 2006, 125, 1269-1281.	28.9	380
207	Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 2006, 441, 523-527.	27.8	362
208	PML inhibits HIF-1 α translation and neoangiogenesis through repression of mTOR. Nature, 2006, 442, 779-785.	27.8	354
209	Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays. Journal of Clinical Oncology, 2006, 24, 778-789.	1.6	513
210	Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes and Cancer, 2006, 45, 447-454.	2.8	133
211	Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations <i>In vivo</i> . Cancer Research, 2006, 66, 7639-7646.	0.9	96
212	Autocrine PDGFR signaling promotes mammary cancer metastasis. Journal of Clinical Investigation, 2006, 116, 1561-1570.	8.2	307
213	Altered expression of DNA double-strand repair genes Ku70 and Ku80 in carcinomas of the oral cavity. Anticancer Research, 2006, 26, 2101-5.	1.1	10
214	Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Research, 2006, 26, 2107-12.	1.1	11
215	Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncology Reports, 2006, 16, 807-10.	2.6	14
216	Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocyctomas. Anticancer Research, 2006, 26, 3461-5.	1.1	1

#	ARTICLE	IF	CITATIONS
217	A Novel Logistic Model Based on Clinicopathological Features Predicts Microsatellite Instability in Colorectal Carcinomas. Diagnostic Molecular Pathology, 2005, 14, 213-223.	2.1	11
218	Gene expression profiling in single cells within tissue. Nature Methods, 2005, 2, 663-665.	19.0	52
219	A microRNA polycistron as a potential human oncogene. Nature, 2005, 435, 828-833.	27.8	3,390
220	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature, 2005, 436, 807-811.	27.8	419
221	Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 2005, 436, 725-730.	27.8	1,768
222	A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. Clinical Cancer Research, 2005, 11, 3836-3845.	7.0	109
223	Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes and Development, 2005, 19, 1779-1786.	5.9	101
224	Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. Clinical Cancer Research, 2005, 11, 3296-3302.	7.0	61
225	p73 ^{Δ2} -Mediated Apoptosis Requires p57kip2 Induction and IEX-1 Inhibition. Cancer Research, 2005, 65, 2186-2192.	0.9	39
226	Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism. Clinical Cancer Research, 2005, 11, 1999-2007.	7.0	194
227	Differential exoprotease activities confer tumor-specific serum peptidome patterns. Journal of Clinical Investigation, 2005, 116, 271-284.	8.2	683
228	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433, 278-285.	27.8	461
229	A Novel Multiplexing, Polymerase Chain Reaction-Based Assay for the Analysis of Chromosome 18q Status in Colorectal Cancer. Journal of Molecular Diagnostics, 2005, 7, 478-485.	2.8	5
230	Cytokeratin expression correlates with aneuploidy in cytological specimens of melanoma metastases. Anticancer Research, 2005, 25, 2789-92.	1.1	6
231	Relationship of nm23 expression to proliferation and prognosis in malignant melanomas of the oral cavity. In Vivo, 2005, 19, 1093-6.	1.3	5
232	Proposal of a new grading system for malignant fibrous histiocytomas. Anticancer Research, 2005, 25, 4293-8.	1.1	0
233	Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin. Clinical Cancer Research, 2004, 10, 1835-1842.	7.0	32
234	Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins. Journal of the National Cancer Institute, 2004, 96, 269-279.	6.3	304

#	ARTICLE	IF	CITATIONS
235	Role of Dok-1 and Dok-2 in Leukemia Suppression. Journal of Experimental Medicine, 2004, 200, 1689-1695.	8.5	82
236	High-resolution characterization of the pancreatic adenocarcinoma genome. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9067-9072.	7.1	246
237	Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature Genetics, 2004, 36, 906-912.	21.4	74
238	The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Medicine, 2004, 10, 484-486.	30.7	536
239	Analysis of adenomatous polyposis coli gene expression, APC locus-microsatellite instability and APC promoter methylation in the progression of melanocytic tumours. Modern Pathology, 2004, 17, 1539-1544.	5.5	16
240	Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 2004, 428, 332-337.	27.8	898
241	Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature, 2004, 430, 797-802.	27.8	517
242	Genetic and Immunophenotype Analyses of TP53 in Bladder Cancer. Diagnostic Molecular Pathology, 2004, 13, 217-223.	2.1	36
243	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	1.4	64
244	Critical Role of Dok-1 and Dok-2 in Leukemia Suppression.. Blood, 2004, 104, 2951-2951.	1.4	0
245	Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases. Anticancer Research, 2004, 24, 981-6.	1.1	11
246	Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Molecular Cancer Therapeutics, 2004, 3, 921-32.	4.1	54
247	Cytokeratin positivity in paraffin-embedded malignant melanomas: comparative study of KL1, A4 and Lu5 antibodies. Anticancer Research, 2004, 24, 3203-7.	1.1	13
248	Analysis of the p53-hMDM2-p21 (WAF1/CIP1) Cell Cycle Regulation Pathway in Malignant Fibrous Histiocytomas. Cancer Genomics and Proteomics, 2004, 1, 419-426.	2.0	0
249	Quantitative Analysis of Ku70 and Ku80 mRNA Gene Expression in Melanoma Brain Metastases. Correlation with Immunohistochemistry and Hybridization. Cancer Genomics and Proteomics, 2004, 1, 225-230.	2.0	2
250	MDM2 and Prognosis. Molecular Cancer Research, 2004, 2, 1-8.	3.4	189
251	p27 as a target for cancer therapeutics. Cancer Cell, 2003, 3, 111-115.	16.8	146
252	A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3, 537-549.	16.8	2,325

#	ARTICLE	IF	CITATIONS
253	p27 deficiency desensitizes Rb ^{+/+} cells to signals that trigger apoptosis during pituitary tumor development. <i>Oncogene</i> , 2003, 22, 361-369.	5.9	27
254	Oncogenes in melanoma. <i>Oncogene</i> , 2003, 22, 3087-3091.	5.9	107
255	Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. <i>Oncogene</i> , 2003, 22, 5298-5305.	5.9	48
256	Expression Profiling of Osteosarcoma Cells Transfected with MDR1 and NEO Genes: Regulation of Cell Adhesion, Apoptosis, and Tumor Suppression-Related Genes. <i>Laboratory Investigation</i> , 2003, 83, 507-517.	3.7	25
257	Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis. <i>Modern Pathology</i> , 2003, 16, 742-751.	5.5	96
258	An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. <i>Nature Genetics</i> , 2003, 33, 396-400.	21.4	342
259	Histone Deacetylase Inhibitors: Assays to Assess Effectiveness In Vitro and In Vivo. <i>Methods in Enzymology</i> , 2003, 376, 199-205.	1.0	15
260	Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis. <i>Science</i> , 2003, 300, 1155-1159.	12.6	1,474
261	Gene Discovery in Bladder Cancer Progression using cDNA Microarrays. <i>American Journal of Pathology</i> , 2003, 163, 505-516.	3.8	177
262	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics. <i>American Journal of Pathology</i> , 2003, 163, 691-700.	3.8	207
263	Tumor Suppressor Role of KiSS-1 in Bladder Cancer. <i>American Journal of Pathology</i> , 2003, 162, 609-617.	3.8	148
264	Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification. <i>Science</i> , 2003, 299, 259-262.	12.6	387
265	p73 ^{Δ116} Regulation by Chk1 in Response to DNA Damage. <i>Molecular and Cellular Biology</i> , 2003, 23, 8161-8171.	2.3	73
266	Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 406-412.	1.6	76
267	Comparison of Gene Expression Profiles in Laser-Microdissected, Nonembedded, and OCT-Embedded Tumor Samples by Oligonucleotide Microarray Analysis. <i>Clinical Chemistry</i> , 2003, 49, 2096-2100.	3.2	16
268	Classification of Clear-Cell Sarcoma as a Subtype of Melanoma by Genomic Profiling. <i>Journal of Clinical Oncology</i> , 2003, 21, 1775-1781.	1.6	177
269	Pten Dose Dictates Cancer Progression in the Prostate. <i>PLoS Biology</i> , 2003, 1, e59.	5.6	593
270	Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. <i>Cancer Research</i> , 2003, 63, 179-85.	0.9	30

#	ARTICLE	IF	CITATIONS
271	Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. <i>Cancer Research</i> , 2003, 63, 2872-80.	0.9	208
272	Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. <i>Clinical Cancer Research</i> , 2003, 9, 2613-9.	7.0	54
273	Tumor promotion by Mdm2 splice variants unable to bind p53. <i>Cancer Research</i> , 2003, 63, 5703-6.	0.9	60
274	Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. <i>Cancer Research</i> , 2003, 63, 7799-806.	0.9	158
275	p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5642-51.	7.0	51
276	HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1803-1806.	6.3	74
277	The Precrystalline Cytoplasmic Granules of Alveolar Soft Part Sarcoma Contain Monocarboxylate Transporter 1 and CD147. <i>American Journal of Pathology</i> , 2002, 160, 1215-1221.	3.8	109
278	Amplification of the 3q26.3 Locus Is Associated with Progression to Invasive Cancer and Is a Negative Prognostic Factor in Head and Neck Squamous Cell Carcinomas. <i>American Journal of Pathology</i> , 2002, 161, 365-371.	3.8	86
279	Clinical Significance of Molecular Expression Profiles of H4rthle Cell Tumors of the Thyroid Gland Analyzed via Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 160, 175-183.	3.8	79
280	Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. <i>American Journal of Pathology</i> , 2002, 161, 1199-1206.	3.8	240
281	The ETS Protein MEF Plays a Critical Role in Perforin Gene Expression and the Development of Natural Killer and NK-T Cells. <i>Immunity</i> , 2002, 17, 437-449.	14.3	173
282	Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent. <i>Journal of Clinical Oncology</i> , 2002, 20, 2980-2987.	1.6	61
283	Differential Expression of DNA Nonhomologous End-Joining Proteins Ku70 and Ku80 in Melanoma Progression. <i>Modern Pathology</i> , 2002, 15, 426-433.	5.5	17
284	Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. <i>Clinical Cancer Research</i> , 2002, 8, 171-9.	7.0	104
285	p63 expression profiles in human normal and tumor tissues. <i>Clinical Cancer Research</i> , 2002, 8, 494-501.	7.0	378
286	Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2002, 8, 679-83.	7.0	132
287	Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. <i>Clinical Cancer Research</i> , 2002, 8, 782-7.	7.0	55
288	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. <i>Clinical Cancer Research</i> , 2002, 8, 986-93.	7.0	357

#	ARTICLE	IF	CITATIONS
289	Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. <i>Anticancer Research</i> , 2002, 22, 193-6.	1.1	6
290	Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. <i>Clinical Cancer Research</i> , 2002, 8, 3226-31.	7.0	85
291	Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. <i>International Journal of Molecular Medicine</i> , 2002, 10, 707-11.	4.0	11
292	Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. <i>Cancer Research</i> , 2002, 62, 6973-80.	0.9	144
293	Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. <i>Clinical Cancer Research</i> , 2002, 8, 3841-9.	7.0	49
294	Validation of Tissue Microarrays for Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic Tumors. <i>American Journal of Pathology</i> , 2001, 158, 1245-1251.	3.8	362
295	Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice. <i>Science</i> , 2001, 293, 293-297.	12.6	1,194
296	High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. <i>Cancer</i> , 2001, 92, 869-874.	4.1	89
297	Molecular analyses of the mitotic checkpoint components hMAD2, hBUB1 and hBUB3 in human cancer. <i>International Journal of Cancer</i> , 2001, 95, 223-227.	5.1	92
298	Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 225-232.	2.5	23
299	Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model. <i>Laboratory Investigation</i> , 2001, 81, 895-903.	3.7	61
300	Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations. <i>Laboratory Investigation</i> , 2001, 81, 1331-1338.	3.7	245
301	Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. <i>Nature Genetics</i> , 2001, 27, 222-224.	21.4	458
302	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. <i>Nature</i> , 2001, 409, 207-211.	27.8	901
303	Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. <i>Cancer Genetics and Cytogenetics</i> , 2001, 125, 131-138.	1.0	18
304	Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue Microarrays. <i>Modern Pathology</i> , 2001, 14, 1270-1276.	5.5	48
305	Mzf1 controls cell proliferation and tumorigenesis. <i>Genes and Development</i> , 2001, 15, 1625-1630.	5.9	117
306	Applications of Molecular Diagnostics: Solid Tumor Genetics Can Determine Clinical Treatment Protocols. <i>Modern Pathology</i> , 2001, 14, 254-257.	5.5	12

#	ARTICLE	IF	CITATIONS
307	Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression. Journal of Experimental Medicine, 2001, 193, 521-530.	8.5	145
308	The 1999 Fred W. Stewart Award. American Journal of Surgical Pathology, 2000, 24, 295.	3.7	0
309	Evaluation of the Performance of a p53 Sequencing Microarray Chip Using 140 Previously Sequenced Bladder Tumor Samples. Clinical Chemistry, 2000, 46, 1555-1561.	3.2	99
310	Genetic and Molecular Markers of Urothelial Premalignancy and Malignancy. Scandinavian Journal of Urology and Nephrology, 2000, 34, 82-93.	1.4	61
311	Alterations of Cell Cycle Regulators in Localized Synovial Sarcoma. American Journal of Pathology, 2000, 156, 977-983.	3.8	84
312	Apoptosis, proliferation, and p27 expression during vessel wall healing: Time course study in a mouse model of transluminal femoral artery injury. Journal of Vascular Surgery, 2000, 32, 1022-1029.	1.1	24
313	MUTATION OF CELL CYCLE REGULATORS AND THEIR IMPACT ON SUPERFICIAL BLADDER CANCER. Urologic Clinics of North America, 2000, 27, 83-102.	1.8	47
314	Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. Atherosclerosis, 2000, 153, 315-322.	0.8	50
315	DNA Microchips: Technical and Practical Considerations. Current Organic Chemistry, 2000, 4, 945-971.	1.6	29
316	Prognostic Significance of Transcription Factor E2F-1 in Bladder Cancer: Genotypic and Phenotypic Characterization. Journal of the National Cancer Institute, 1999, 91, 874-881.	6.3	54
317	At the Crossroads of Inflammation and Tumorigenesis. Journal of Experimental Medicine, 1999, 190, 1367-1370.	8.5	125
318	Essential role for oncogenic Ras in tumour maintenance. Nature, 1999, 400, 468-472.	27.8	855
319	Impaired Fas Response and Autoimmunity in Pten+/- Mice. Science, 1999, 285, 2122-2125.	12.6	490
320	Deletions of the INK4A Gene in Superficial Bladder Tumors. American Journal of Pathology, 1999, 155, 105-113.	3.8	121
321	Deletions of the INK4A Gene Occur in Malignant Peripheral Nerve Sheath Tumors but not in Neurofibromas. American Journal of Pathology, 1999, 155, 1855-1860.	3.8	161
322	Expression of p27kip and Other Cell Cycle Regulators in Malignant Peripheral Nerve Sheath Tumors and Neurofibromas. American Journal of Pathology, 1999, 155, 1885-1891.	3.8	120
323	Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature, 1998, 393, 483-487.	27.8	190
324	Pten is essential for embryonic development and tumour suppression. Nature Genetics, 1998, 19, 348-355.	21.4	1,428

#	ARTICLE	IF	CITATIONS
325	Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. , 1998, 83, 490-497.		90
326	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. , 1998, 75, 819-824.		31
327	Ku70. Molecular Cell, 1998, 2, 1-8.	9.7	217
328	The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53. Cell, 1998, 92, 713-723.	28.9	1,412
329	Role of PML in Cell Growth and the Retinoic Acid Pathway. Science, 1998, 279, 1547-1551.	12.6	488
330	Expression of Granulocyte-Macrophage Colony-Stimulating Factor Receptors in Human Prostate Cancer. Blood, 1998, 91, 1037-1043.	1.4	44
331	Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. International Journal of Cancer, 1998, 75, 819-824.	5.1	2
332	Lipopolysaccharide Induces Disseminated Endothelial Apoptosis Requiring Ceramide Generation. Journal of Experimental Medicine, 1997, 186, 1831-1841.	8.5	412
333	Ku70 Is Required for DNA Repair but Not for T Cell Antigen Receptor Gene Recombination In Vivo. Journal of Experimental Medicine, 1997, 186, 921-929.	8.5	249
334	Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World Journal of Urology, 1997, 15, 112-119.	2.2	14
335	Bcl-2 and Bax expression in thyroid tumours An immunohistochemical and Western blot analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 430, 125-130.	2.8	39
336	Genetic studies and molecular markers of bladder cancer. , 1997, 13, 319-327.		49
337	Chromosome 16 in primary prostate cancer: A microsatellite analysis. , 1997, 71, 580-584.		22
338	Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. International Journal of Cancer, 1997, 73, 42-49.	5.1	254
339	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. , 1997, 73, 50-56.		212
340	Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. International Journal of Cancer, 1997, 73, 50-56.	5.1	2
341	Genetic studies and molecular markers of bladder cancer. Journal of Surgical Oncology, 1997, 13, 319-327.	1.4	1
342	Acid Sphingomyelinase-Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis. Cell, 1996, 86, 189-199.	28.9	780

#	ARTICLE	IF	CITATIONS
343	Role of the INK4a Locus in Tumor Suppression and Cell Mortality. <i>Cell</i> , 1996, 85, 27-37.	28.9	1,512
344	Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. , 1996, 69, 110-113.		34
345	Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines. , 1996, 68, 514-519.		16
346	Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 419-426.	2.1	20
347	A Case-Series Study of p53 Nuclear Overexpression in Early-Stage Stomach Cancer. <i>Annals of the New York Academy of Sciences</i> , 1995, 768, 269-271.	3.8	2
348	p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns. <i>International Journal of Cancer</i> , 1994, 56, 347-353.	5.1	220
349	Bladder cancer: advances in biology and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 1994, 16, 33-70.	4.4	7
350	Preselection of Patients with High TAG-72 Antigen Expression Leads to Targeting of 94% of Known Metastatic Tumor Sites with Monoclonal Antibody I-131-CC49. <i>Cancer Investigation</i> , 1994, 12, 551-558.	1.3	6
351	Expression of Transforming Growth Factor- β and the Epidermal Growth Factor Receptor in Human Prostate Tissues. <i>Journal of Urology</i> , 1994, 152, 2120-2124.	0.4	89
352	Biological Study of R24 Mouse Monoclonal Antibody in Patients Undergoing Thoracotomy for Pulmonary Metastases from Soft Tissue Sarcoma. <i>Cancer Investigation</i> , 1994, 12, 20-25.	1.3	8
353	Clinical and Pathobiological Effects of Neoadjuvant Total Androgen Ablation Therapy on Clinically Localized Prostatic Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 1994, 18, 979-991.	3.7	133
354	P-glycoprotein expression in brain tumors. <i>Journal of Neuro-Oncology</i> , 1992, 14, 37-43.	2.9	68
355	Cell surface differentiation antigens of normal urothelium and bladder tumors. <i>Journal of Surgical Oncology</i> , 1992, 8, 293-299.	1.4	7
356	Expression of blood group antigens in bladder cancer: Current concepts. <i>Journal of Surgical Oncology</i> , 1992, 8, 308-315.	1.4	14
357	Blood group antigens in normal and neoplastic urothelium. <i>Journal of Cellular Biochemistry</i> , 1992, 50, 50-55.	2.6	16
358	Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. <i>Cancer</i> , 1992, 70, 633-638.	4.1	97
359	The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. <i>Cell</i> , 1991, 66, 173-183.	28.9	521
360	The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. <i>Cell</i> , 1991, 66, 395-403.	28.9	881

#	ARTICLE	IF	CITATIONS
361	Cell-surface antigens of human lung tumors detected by mouse monoclonal antibodies: Definition of blood-group- and non-blood-group-related antigenic systems. International Journal of Cancer, 1990, 46, 1007-1013.	5.1	15
362	Altered Expression of the Retinoblastoma Gene Product in Human Sarcomas. New England Journal of Medicine, 1990, 323, 1457-1462.	27.0	212
363	Association of the Lewis Blood-Group Phenotype with Recurrent Urinary Tract Infections in Women. New England Journal of Medicine, 1989, 320, 773-777.	27.0	240
364	Tissue Distribution of GD3 Ganglioside Detected by Mouse Monoclonal Antibody R24. American Journal of Dermatopathology, 1989, 11, 577-581.	0.6	19
365	Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells With Monoclonal Antibodies. Journal of Investigative Dermatology, 1988, 90, 459-466.	0.7	78
366	HIV antigen in the brains of patients with the AIDS dementia complex. Annals of Neurology, 1987, 21, 490-496.	5.3	308
367	Changes in Cell Surface Glycoprotein Expression During Differentiation of Human Keratinocytes. Journal of Investigative Dermatology, 1987, 89, 500-506.	0.7	57
368	Immunohistologic expression of blood-group antigens in normal human gastrointestinal tract and colonic carcinoma. International Journal of Cancer, 1986, 37, 667-676.	5.1	63
369	Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. International Journal of Cancer, 1985, 35, 469-475.	5.1	42
370	Immunohistochemical localization of Ia nuclear antigen in brain. Journal of Neuroimmunology, 1985, 9, 307-319.	2.3	13
371	Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody. Brain Research, 1984, 324, 190-194.	2.2	45